keyword
MENU ▼
Read by QxMD icon Read
search

Atypical antipsychotics

keyword
https://www.readbyqxmd.com/read/28515915/superior-effects-of-quetiapine-compared-with-aripiprazole-and-iloperidone-on-mk-801-induced-olfactory-memory-impairment-in-female-mice
#1
Ahmet Mutlu, Oguz Mutlu, Guner Ulak, Furuzan Akar, Havva Kaya, Faruk Erden, Pelin Tanyeri
Cognitive dysfunction is commonly observed in schizophrenic patients and the administration of antipsychotic treatments results in different outcomes. Although the typical antipsychotic treatments, such as haloperidol, appear to be unable to improve cognition dysfunction, the atypical antipsychotic drugs (quetiapine, aripiprazole and iloperidone) exert a beneficial effect. The purpose of the current study was to investigate the effects of atypical antipsychotics on olfactory memory in mice, utilizing the social transmission of food preference (STFP) tests to evaluate the effects of drugs on MK-801-induced cognitive dysfunction...
May 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28509906/therapeutic-efficacy-of-atypical-antipsychotic-drugs-by-targeting-multiple-stress-related-metabolic-pathways
#2
H L Cai, P Jiang, Q Y Tan, R L Dang, M M Tang, Y Xue, Y Deng, B K Zhang, P F Fang, P Xu, D X Xiang, H D Li, J K Yao
Schizophrenia (SZ) is considered to be a multifactorial brain disorder with defects involving many biochemical pathways. Patients with SZ show variable responses to current pharmacological treatments of SZ because of the heterogeneity of this disorder. Stress has a significant role in the pathophysiological pathways and therapeutic responses of SZ. Atypical antipsychotic drugs (AAPDs) can modulate the stress response of the hypothalamic-pituitary-adrenal (HPA) axis and exert therapeutic effects on stress by targeting the prefrontal cortex (PFC) and hippocampus...
May 16, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28499974/prefrontal-cortical-glutathione-dependent-defense-and-proinflammatory-mediators-in-chronically-isolated-rats-modulation-by-fluoxetine-or-clozapine
#3
Nevena Todorović, Dragana Filipović
Chronic psychosocial stress modulates brain antioxidant systems and causes neuroinflammation that plays a role in the pathophysiology of depression. Although the antidepressant fluoxetine (FLX) represents the first-line treatment for depression and the atypical antipsychotic clozapine (CLZ) is considered as a second-line treatment for psychotic disorders, the downstream mechanisms of action of these treatments, beyond serotonergic or dopaminergic signaling, remain elusive. We examined behavioral changes, glutathione (GSH)-dependent defense and levels of proinflammatory mediators in the prefrontal cortex (PFC) of adult male Wistar rats exposed to 21days of chronic social isolation (CSIS)...
May 10, 2017: Neuroscience
https://www.readbyqxmd.com/read/28499900/lurasidone-in-post-menopausal-females-with-major-depressive-disorder-with-mixed-features-post-hoc-analysis-of-a-placebo-controlled-trial
#4
John Sramek, Anthony Loebel, Michael Murphy, Yongcai Mao, Andrei Pikalov, Neal R Cutler
BACKGROUND: Several studies have found that depressed, post-menopausal females may respond differently to antidepressants compared to pre-menopausal females. The atypical antipsychotic lurasidone, whose mechanism of action differs from SSRIs and other standard antidepressants, was shown in a 6-week randomized, flexible-dose, placebo-controlled study (n=209), to be effective in treating major depressive disorder (MDD) with mixed features (subthreshold hypomanic symptoms). This post-hoc analysis assessed the efficacy of lurasidone in this study by menopausal status...
May 9, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28498089/changes-in-bmi-in-hospitalized-patients-during-treatment-with-antipsychotics-depending-on-gender-and-other-factors
#5
Lenka Sušilová, Eva Češková, David Hampel, Aleš Sušil, Jan Šimůnek
OBJECTIVE: To investigate the differences in body mass index (BMI) changes between men and women during hospitalization. METHODS: The retrospective study monitored demographic and clinical data of 462 schizophrenic patients hospitalized 737 times between 2006 and 2011. BMI analysis was performed on patients on antipsychotic medication hospitalized longer than four days. RESULTS: Patients with an initial BMI < 25 gained more weight than patients with a BMI > 25 (3...
February 24, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28494390/bipolar-patients-treated-with-long-acting-injectable-risperidone-in-taiwan-a-1-year-mirror-image-study-using-a-national-claims-database
#6
Ming H Hsieh, Po-Ya Chuang, Chi-Shin Wu, Ching-Jui Chang, Pei-Fang Chung, Chao-Hsiun Tang
OBJECTIVE: Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. METHOD: 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007-2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data...
May 3, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28493654/the-us-food-and-drug-administration-s-perspective-on-the-new-antipsychotic-pimavanserin
#7
Mitchell V Mathis, Brendan M Muoio, Paul Andreason, Amy M Avila, Tiffany Farchione, Aisar Atrakchi, Robert J Temple
OBJECTIVE: To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. We describe the regulatory and clinical issues important to the FDA's approval of this New Drug Application, with special focus on the risk-benefit balance. We also describe a new labeling feature that presents additional efficacy data to clinicians...
May 9, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28492956/relationship-between-the-rs1414334-c-g-polymorphism-in-the-htr2c-gene-and-smoking-in-patients-treated-with-atypical-antipsychotics
#8
José María Rico-Gomis, Antonio Palazón-Bru, Irene Triano-García, Luis Fabián Mahecha-García, Ana García-Monsalve, Andrés Navarro-Ruiz, Berta Villagordo-Peñalver, Alicia Martínez-Hortelano, Vicente Francisco Gil-Guillén
An association has been found between the C allele of the rs1414334 polymorphism in the HTR2C gene and the metabolic syndrome in psychiatric patients. However, no study has yet evaluated whether this allele is associated with smoking. To assess this issue, therefore, we performed a cross-sectional study with a sample of 166 adult patients treated with atypical antipsychotics in 2012-2013 in a region of Spain. The primary variable was the presence of the C allele of the rs1414334 polymorphism in the HTR2C gene...
April 12, 2017: Adicciones
https://www.readbyqxmd.com/read/28490709/-research-progress-in-mechanisms-and-clinical-application-for-blonanserin-and-lurasidone-in-improving-cognitive-function-of-schizophrenia
#9
Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang Li
Cognition deficit is one of the most common symptoms of schizophrenia, including abstract thinking and memory, and attention deficits. Previous studies have suggested that the improvement of cognition is very important for the recovery of disease and social function for the patients. Recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. This review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia...
April 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28489950/the-return-of-d4-dopamine-receptor-antagonists-in-drug-discovery
#10
Craig W Lindsley, Corey R Hopkins
The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clinical efficacy of clozapine. Coupled with genetic association of the DRD4 gene with various CNS disorders, multiple companies launched discovery programs to develop selective D4 antagonists. Merck's D4 antagonist L-745,870 was the first to reach the clinic, where it was found to be ineffective in schizophrenia patients, and other groups failed to recapitulate some of the genetic data...
May 10, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28487307/aripiprazole-induced-hypersensitivity-pneumonitis
#11
Kulothungan Gunasekaran, Swetha Murthi, Jeffrey Jennings, Nazir Lone
Aripiprazole is an atypical antipsychotic agent commonly used in the management of schizophrenia. Aripiprazole has not been reported to have an association with interstitial lung disease. We describe a case of a 36-year-old woman who began to experience respiratory issues shortly after starting aripiprazole and presented to us 4 years later with progressive exertional shortness of breath. High-resolution CT of the chest showed a bilateral ground glass pattern. Video-assisted thoracoscopy with biopsy revealed alveolar septal thickening and an inflammatory infiltrate composed mainly of lymphocytes, suggestive of chronic hypersensitivity pneumonitis...
May 9, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28482249/association-among-serum-cortisol-dehydroepiandrosterone-sulfate-levels-and-psychiatric-symptoms-in-men-with-chronic-schizophrenia
#12
Rui Peng, Yan Li
PURPOSE: The purpose of this study was to examine possible associations of serum levels of cortisol and dehydroepiandrosterone-sulfate (DHEA-S) with psychiatric symptoms in men with chronic schizophrenia. METHODS: This retrospective study involved 162 men with schizophrenia and 138 age-matched healthy controls, for whom data were collected on demographic characteristics, age at disease onset, disease duration, positive and negative syndrome scale (PANSS) scores, and history of atypical antipsychotic treatment...
March 27, 2017: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/28478793/antipsychotic-prescribing-practices-in-those-with-parkinsonism-adherence-to-guidelines
#13
Heather B Rigby, Sara Rehan, Barbara Hill-Taylor, Kara Matheson, Ingrid Sketris
Several evidence-informed treatment guidelines recommend against the use of typical antipsychotics in patients with Parkinson's disease; of the atypical antipsychotics, clozapine and quetiapine are preferred. The purpose of this study is to determine the frequency with which potentially inappropriate antipsychotics are dispensed to older adults in Nova Scotia who are on levodopa-containing medications. In this cohort, 59.9% were dispensed a preferred atypical antipsychotic and 12.6% a potentially harmful typical antipsychotic...
May 8, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/28478771/evaluation-of-the-long-term-safety-and-tolerability-of-cariprazine-in-patients-with-schizophrenia-results-from-a-1-year-open-label-study
#14
Andrew J Cutler, Suresh Durgam, Yao Wang, Raffaele Migliore, Kaifeng Lu, István Laszlovszky, György Németh
OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. The efficacy and safety of cariprazine was established in three randomized, double-blind, placebo-controlled, 6-week trials in patients with acute exacerbation of schizophrenia. This 53-week study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
May 8, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28474733/practitioner-review-the-effects-of-atypical-antipsychotics-and-mood-stabilisers-in-the-treatment-of-depressive-symptoms-in-paediatric-bipolar-disorder
#15
REVIEW
Tobias Atkin, Nicolas Nuñez, Gabriella Gobbi
BACKGROUND: The management of depressive and mixed symptoms in children and adolescents with bipolar disorder (BD) remains a matter of debate. The goal of this review is, thus, to systematically examine the impact of atypical antipsychotics (AAPs) and mood stabilisers in the treatment of bipolar depression and/or mixed states. METHODS: A literature search was conducted for studies assessing the efficacy of pharmacological treatments for bipolar disorder type I, type II and not otherwise specified with a recent depressive, mixed or manic episode (with depressive symptoms) following DSM-IV criteria in children and adolescents as either acute or maintenance treatment...
May 5, 2017: Journal of Child Psychology and Psychiatry, and Allied Disciplines
https://www.readbyqxmd.com/read/28472198/clozapine-counteracts-a-ketamine-induced-depression-of-hippocampal-prefrontal-neuroplasticity-and-alters-signaling-pathway-phosphorylation
#16
Marion Rame, Dorian Caudal, Esther Schenker, Per Svenningsson, Michael Spedding, Thérèse M Jay, Bill P Godsil
Single sub-anesthetic doses of ketamine can exacerbate the symptoms of patients diagnosed with schizophrenia, yet similar ketamine treatments rapidly reduce depressive symptoms in major depression. Acute doses of the atypical antipsychotic drug clozapine have also been shown to counteract ketamine-induced psychotic effects. In the interest of understanding whether these drug effects could be modeled with alterations in neuroplasticity, we examined the impact of acutely-administered ketamine and clozapine on in vivo long-term potentiation (LTP) in the rat's hippocampus-to-prefrontal cortex (H-PFC) pathway...
2017: PloS One
https://www.readbyqxmd.com/read/28469583/commentary-a-randomized-double-blind-placebo-controlled-trial-of-metformin-treatment-of-weight-gain-associated-with-initiation-of-atypical-antipsychotic-therapy-in-children-and-adolescents
#17
COMMENT
https://www.readbyqxmd.com/read/28465867/differences-in-antipsychotic-related-adverse-events-in-adult-pediatric-and-geriatric-populations
#18
Hersh Sagreiya, Yi-Ren Chen, Narmadan A Kumarasamy, Karthik Ponnusamy, Doris Chen, Amar K Das
In recent years, antipsychotic medications have increasingly been used in pediatric and geriatric populations, despite the fact that many of these drugs were approved based on clinical trials in adult patients only. Preliminary studies have shown that the "off-label" use of these drugs in pediatric and geriatric populations may result in adverse events not found in adults. In this study, we utilized the large-scale U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (AERS) database to look at differences in adverse events from antipsychotics among adult, pediatric, and geriatric populations...
February 26, 2017: Curēus
https://www.readbyqxmd.com/read/28464773/the-role-of-atypical-antipsychotics-in-sexuality-road-to-recovery-in-schizophrenia
#19
Raja Lope Adam, Hatta Sidi, Marhani Midin, Hazli Zakaria, Srijit Das, Khairi Che Mat
Sexuality is an important dimension in human beings as a form of expression of individuality. For many decades, sexual functioning has been a neglected area among patients suffering from schizophrenia. It was a presumption that patients with schizophrenia could be asexual and this could be secondary to overwhelming situations of delusion, hallucination, hostility and negative symptoms among others. The deficient in sexual functioning are due to innate factors, i.e. negative symptoms (apathy, avolition and amotivation) and also as a result of prefrontal dysfunction, i...
May 2, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28463343/biological-treatment-of-acute-agitation-or-aggression-with-schizophrenia-or-bipolar-disorder-in-the-inpatient-setting
#20
Christoph U Correll, Xin Yu, Yutao Xiang, John M Kane, Prakash Masand
BACKGROUND: Schizophrenia and bipolar disorders are chronic illnesses that commonly present with symptoms of acute agitation and aggression. These symptoms must be managed rapidly to prevent potential harm to the patient and others, including their caregivers, peers, and health care workers. A number of treatment options are available to clinicians to manage acute agitation and aggression, including non-pharmacologic behavioral and environmental de-escalation strategies, as well as biological treatment options such as pharmacologic agents and electroconvulsive therapy...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
keyword
keyword
73041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"